Rep. Steve Cohen (D-Tenn.) has proposed a 2026 bill that would overhaul federal drug scheduling by shifting final classification decisions from the DEA to HHS, splitting abuse risk from medical value, descheduling marijuana and THC, and easing research barriers. For clinicians, that could change how drugs are studied, how therapeutic benefit is officially recognized, and how shortages, prescribing policy, and criminal penalties ripple back into patient care.

The Move

• Cohen’s Public Health and Research Reforms in Controlled Substances Act of 2026 would replace the current single scheduling framework with two ratings: a Roman numeral for misuse and public-health risk, and a letter grade for therapeutic value.

• The bill would move authority over medical usefulness, drug-related risk, and researcher registration from the DEA to HHS, while requiring expert committee review and public reasoning for scheduling decisions.

• Marijuana and tetrahydrocannabinols would be removed from the federal controlled-substance schedules, retroactively applying to past offenses, pending cases, convictions, and juvenile adjudications.

• The legislation also would reduce several mandatory minimum sentencing provisions and require reconsideration of current classifications on a two-year deadline for 32 named substances and eight years for most others.

Why It Matters For Care

• The bill explicitly recognizes a core clinical reality: a drug can carry high misuse or overdose risk and still have substantial medical value, as with fentanyl’s role in anesthesia and analgesia.

• That shift could make it easier to study controlled substances now trapped in a catch-22, where regulators cite limited evidence of benefit while maintaining restrictions that impede the research needed to generate that evidence.

• Faster HHS registration pathways for qualifying researchers could expand preclinical and clinical investigation of substances relevant to pain, addiction, psychiatry, and palliative care.

• The proposal also forces officials to consider whether scheduling itself harms public health by driving substitution, contamination, or loss of access to substances patients may be using to reduce reliance on more dangerous drugs.

Between The Lines

• This is a direct challenge to the decades-old model in which law enforcement, not health officials, makes the ultimate call on whether a substance has accepted medical use.

• The bill reflects growing frustration with a system shaped as much by politics, stigma, and prohibition-era incentives as by clinical evidence.

• It also nods to real-world care disruptions: federal opioid production quotas have contributed to shortages of injectable opioids in hospitals, affecting surgical patients and those on ventilators, even though the bill would transfer quotas to HHS rather than eliminate them.

• Still, the proposal preserves major constraints, including criminal penalties for some possession, emergency scheduling with limited review, and continued FDA authority over cannabis products.

What To Watch

• Cohen is retiring, making passage in the lame-duck session unlikely; the more realistic role for the bill may be as a template for the next Congress.

• Watch whether lawmakers keep the bill’s two-axis scheduling model or revert to the current approach that conflates abuse risk with medical usefulness.

• Clinicians should also track how any final measure handles research registration, production quotas, and review deadlines, since those details would shape bedside access, evidence generation, and supply stability.

• Marijuana descheduling, if enacted, would not end federal oversight: FDA authority would remain, leaving future fights over cannabis products to regulators, courts, and possibly the states.

Source: Reason